Navigation Links
Basilea Reports Positive Re-treatment Results from a Second Phase,III Trial of Alitretinoin for Patients with Severe Chronic Hand,Eczema

in an open-label fashion for another 12 to 24 weeks. Forty-seven percent (47%) achieved a response as defined by clear or almost clear hands. These results further confirm the efficacy of alitretinoin in patients with CHE refractory to topical therapy.

Alitretinoin was generally well tolerated with a safety profile similar to that reported in previous phase II and phase III clinical studies. The most frequent adverse events were headache and blood lipid elevations.

Dr. Anthony Man, CEO of Basilea said, "Because of the relapsing nature of Chronic Hand Eczema it was important for patients and treating physicians that we further characterize the safety and efficacy of more than one treatment course of alitretinoin. These trial results confirm that alitretinoin is an effective treatment for severe refractory Chronic Hand Eczema. Alitretinoin has the potential to be integrated into pragmatic re-treatment algorithms for these chronically affected patients who have limited treatment options."

About Chronic Hand Eczema (CHE) Hand eczema is a common skin disease and is often chronic and relapsing. It is estimated to affect up to 10% of the general population. The more severe, chronic form of the condition is thought to affect up to 7% of these patients, many of whom do not respond, or no longer respond to topical corticosteroids. Basilea estimates there are at least one million patients in Europe and North America with refractory severe CHE for which currently no approved, effective pharmaceutical treatment is available.

For the patient, severe CHE can be a frustrating and debilitating disease. Patients often suffer for years from erythema, blisters, vesicles, scaling and fissures which can cause chronic pain and functional impairment of the hands. Studies suggest these patients have a significantly reduced quality of life and the majority experience social or emotional distress and sleep disorders. It is reported that up to 20% of sufferers have
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Efficacy and Safety Profile of Basileas Alitretinoin for Severe Refractory Chronic Hand Eczema Confirmed by Data Shown at European Dermatology Congress
2. Scientific Results Presented At ECCMID Demonstrate Well- Differentiated Profile of Basileas Two Phase III Anti- infective Compounds
3. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
4. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
5. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
6. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
7. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
8. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
9. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
10. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
11. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
Post Your Comments:
(Date:7/25/2014)... NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, ... OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE ... JURISDICTION AbbVie (NYSE: ABBV ) today announced financial ... "This was another very strong quarter for AbbVie, ... original guidance and announced plans to merge with Shire, a ...
(Date:7/24/2014)... OVERLAND PARK, Kan. , July 24, 2014 ... licensing of two compounds that will be added ... agreement with Australian-based CIMTECH Pty Ltd, a biotechnology ... and PAR 122 have shown promise in bone ... a license to develop the compounds for the ...
(Date:7/24/2014)... Germany , and MARSEILLE, France ... , Exclusive global license from University of Tokyo ... next-generation sequencing (NGS) gene panels, for blood cancers  ... new test, indicate favorable prognosis for patients with bone ... sees potential for developing companion diagnostics to guide treatment ...
Breaking Medicine Technology:AbbVie Reports Second-Quarter 2014 Financial Results 2AbbVie Reports Second-Quarter 2014 Financial Results 3AbbVie Reports Second-Quarter 2014 Financial Results 4AbbVie Reports Second-Quarter 2014 Financial Results 5AbbVie Reports Second-Quarter 2014 Financial Results 6AbbVie Reports Second-Quarter 2014 Financial Results 7AbbVie Reports Second-Quarter 2014 Financial Results 8AbbVie Reports Second-Quarter 2014 Financial Results 9AbbVie Reports Second-Quarter 2014 Financial Results 10AbbVie Reports Second-Quarter 2014 Financial Results 11AbbVie Reports Second-Quarter 2014 Financial Results 12AbbVie Reports Second-Quarter 2014 Financial Results 13AbbVie Reports Second-Quarter 2014 Financial Results 14AbbVie Reports Second-Quarter 2014 Financial Results 15AbbVie Reports Second-Quarter 2014 Financial Results 16AbbVie Reports Second-Quarter 2014 Financial Results 17AbbVie Reports Second-Quarter 2014 Financial Results 18AbbVie Reports Second-Quarter 2014 Financial Results 19AbbVie Reports Second-Quarter 2014 Financial Results 20AbbVie Reports Second-Quarter 2014 Financial Results 21AbbVie Reports Second-Quarter 2014 Financial Results 22AbbVie Reports Second-Quarter 2014 Financial Results 23AbbVie Reports Second-Quarter 2014 Financial Results 24AbbVie Reports Second-Quarter 2014 Financial Results 25AbbVie Reports Second-Quarter 2014 Financial Results 26AbbVie Reports Second-Quarter 2014 Financial Results 27AbbVie Reports Second-Quarter 2014 Financial Results 28AbbVie Reports Second-Quarter 2014 Financial Results 29AbbVie Reports Second-Quarter 2014 Financial Results 30AbbVie Reports Second-Quarter 2014 Financial Results 31AbbVie Reports Second-Quarter 2014 Financial Results 32AbbVie Reports Second-Quarter 2014 Financial Results 33AbbVie Reports Second-Quarter 2014 Financial Results 34AbbVie Reports Second-Quarter 2014 Financial Results 35AbbVie Reports Second-Quarter 2014 Financial Results 36
... May 15, 2012 Reportlinker.com ... research report is available in ... Global ... Marketing Spend and Sales Strategies ...
... May 15, 2012  Reportlinker.com announces that ... available in its catalogue: ... China Market Analysis, Size, Trends And ... In 2009, the global Osteoporosis drug ...
Cached Medicine Technology:Global Pharmaceutical Survey 2012-2013: Market Trends, Marketing Spend and Sales Strategies in the Global Pharmaceutical Industry 2Global Pharmaceutical Survey 2012-2013: Market Trends, Marketing Spend and Sales Strategies in the Global Pharmaceutical Industry 3Global Pharmaceutical Survey 2012-2013: Market Trends, Marketing Spend and Sales Strategies in the Global Pharmaceutical Industry 4Global Pharmaceutical Survey 2012-2013: Market Trends, Marketing Spend and Sales Strategies in the Global Pharmaceutical Industry 5Global Pharmaceutical Survey 2012-2013: Market Trends, Marketing Spend and Sales Strategies in the Global Pharmaceutical Industry 6Global Pharmaceutical Survey 2012-2013: Market Trends, Marketing Spend and Sales Strategies in the Global Pharmaceutical Industry 7Global Pharmaceutical Survey 2012-2013: Market Trends, Marketing Spend and Sales Strategies in the Global Pharmaceutical Industry 8Global Pharmaceutical Survey 2012-2013: Market Trends, Marketing Spend and Sales Strategies in the Global Pharmaceutical Industry 9Global Pharmaceutical Survey 2012-2013: Market Trends, Marketing Spend and Sales Strategies in the Global Pharmaceutical Industry 10Global Pharmaceutical Survey 2012-2013: Market Trends, Marketing Spend and Sales Strategies in the Global Pharmaceutical Industry 11Global Pharmaceutical Survey 2012-2013: Market Trends, Marketing Spend and Sales Strategies in the Global Pharmaceutical Industry 12Global Pharmaceutical Survey 2012-2013: Market Trends, Marketing Spend and Sales Strategies in the Global Pharmaceutical Industry 13Global Pharmaceutical Survey 2012-2013: Market Trends, Marketing Spend and Sales Strategies in the Global Pharmaceutical Industry 14Global Pharmaceutical Survey 2012-2013: Market Trends, Marketing Spend and Sales Strategies in the Global Pharmaceutical Industry 15Global Pharmaceutical Survey 2012-2013: Market Trends, Marketing Spend and Sales Strategies in the Global Pharmaceutical Industry 16Global Pharmaceutical Survey 2012-2013: Market Trends, Marketing Spend and Sales Strategies in the Global Pharmaceutical Industry 17Global Pharmaceutical Survey 2012-2013: Market Trends, Marketing Spend and Sales Strategies in the Global Pharmaceutical Industry 18Osteoporosis Drug Market- Global And China Market Analysis, Size, Trends And Forecast (2010-2015) 2Osteoporosis Drug Market- Global And China Market Analysis, Size, Trends And Forecast (2010-2015) 3Osteoporosis Drug Market- Global And China Market Analysis, Size, Trends And Forecast (2010-2015) 4
(Date:7/26/2014)... The European gas chromatography reagents report defines and ... of revenue. The gas chromatography reagents market in Europe is ... to grow to around $445.5 million by 2018, at a ... through the TOC of the European gas chromatography reagents market, ... report also provides a glimpse of the segmentation of gas ...
(Date:7/26/2014)... 26, 2014 “Today, we introduce our ... clients all over the world. All these models are ... designed for the UK market,” says the CEO of ... suppliers of women’s special occasion outfits. , Ladies have ... comes. DressesOnlineShops.co.uk is one of the best choices for ...
(Date:7/26/2014)... 2014 According to the ... Vkool.com, this is a comprehensive guide that ... treating all types of disorders related ...     Tinnitus due to Ménière's disease , ... pathway tinnitus ,     Inner, middle or ...
(Date:7/26/2014)... 2014 Studio B Dental in Toronto now ... called Teeth in a Day, gives patients the opportunity to ... of bright, pearly whites with very little recovery time and ... and feel just like natural teeth, and require no special ... Studio B Dental is one of the premiere dental experts ...
(Date:7/26/2014)... According to the Metabolic Enhancement Training program review ... program that helps men lose body fat and build ... program also instructs men how to melt fat and ... in its review that this program includes a series ... ripped and jacked at the same time. Vkool also ...
Breaking Medicine News(10 mins):Health News:Europe Gas Chromatography Reagents Market is Expected to Reach $445.5 million in 2018 - New Report by MicroMarket Monitor 2Health News:Europe Gas Chromatography Reagents Market is Expected to Reach $445.5 million in 2018 - New Report by MicroMarket Monitor 3Health News:Europe Gas Chromatography Reagents Market is Expected to Reach $445.5 million in 2018 - New Report by MicroMarket Monitor 4Health News:Europe Gas Chromatography Reagents Market is Expected to Reach $445.5 million in 2018 - New Report by MicroMarket Monitor 5Health News:Famous Supplier DressesOnlineShops.co.uk Announces Its New Selection of Prom Dresses for the UK Market 2Health News:Tinnitus Miracle Book Review Exposes Thomas Coleman's Guide for Treating Tinnitus – Vkool.com 2Health News:Studio B Dental Improves Patient Smiles with All-on-Four Dental Implants 2Health News:Metabolic Enhancement Training Review Exposes Scott Abel's Program for Bodybuilding – Vkool.com 2Health News:Metabolic Enhancement Training Review Exposes Scott Abel's Program for Bodybuilding – Vkool.com 3
... Trinity College in Dublin has launched a major study to understand ... is headed by Rose Anne Kenny //a professor of Geriatric Medicine. ... older people are amongst the least healthy in Europe and that ... is highest in the EU” , ,She continued to say ...
... Benedict XVI is in a dilemma; whether to preserve ... shift[ing] to a relative yes-sometimes //policy that gives us ... church policy on contraception, abortion and infallibility to new ... editor of a Catholic newspaper. ,Cardinal Javier ...
... bird flu experts have refuted a report on Sunday that ... in southern China, //published in a foreign publication as well ... to scientists in Hong Kong and the United States a ... isolated in the southern Chinese province of Fujian last year, ...
... legal aspects of abortion have become the subject of intense ... throughout history and Since 2000, medically induced abortions (MIAs) death ... toxic shock caused by a Clostridium sordellii infection. This has ... the drugs mifepristone and misoprostol that are usually used in ...
... is back in Bhutan - processed, sealed, frozen and selling ... which arrived here from Phuntsholing on the India-Bhutan border, sold ... consumers, a report in the state-run daily Kuensel said., ... on Oct 11 lifted an eight-month ban on the import ...
... almost 11 percent rise in the number of tuberculosis ... //Bangladeshi communities, latest official figures reveal. ,The ... Britain - from 4,696 in 2004 to 5,310 in ... ,John Watson, head of the Respiratory Diseases Department at ...
Cached Medicine News:Health News:New Bird flu Strain Claims Refuted 2Health News:Medically Induced Abortions (MIAs) Causes More Deaths Due To Infection 2Health News:Indian Chicken Back On Bhutanese Platter 2Health News:TB Cases On The Rise Among British Asians 2
The applicator is designed for a smooth delivery of the solution for surgical procedures....
... Avaulta™ BioSynthetic Mesh ... mesh coated in the ... absorbable, hydrophilic film of ... segments of the Avaulta™ ...
The Repliform Tissue Regeneration Matrix is an acellular human dermal allograft that when surgically implanted is intended to function as a template, facilitating the body's fibroblasts to regenerate...
... Pelvicol® Acellular Collagen Matrix delivers the ... exceptional strength, versatility, and durability in ... the effectiveness of site-specific defect repair ... sterile, biocompatible, crosslinked porcine dermal collagen ...
Medicine Products: